CTNNB1 and hepatocellular carcinoma: The HCC patients with combined TP53 and CTNNB1 mutations had poorer survival than TP53 (Figure 4E) or CTNNB1 (Figure 4F) mutations alone with HR (Mantel-Haenszel), 6.253; 95% CI, 1.334–29.31; log-rank p-value, 0.02; and HR (Mantel-Haenszel), 5.660; 95% CI, 1.199–26.73; log-rank p-value, 0.02, respectively.